Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus TRIANEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus TRIANEX.
FLOVENT DISKUS 50 vs TRIANEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Category C
Category C
Corticosteroid
Corticosteroid